Clinical Trials in Ohio

Showing 6881-6900 of 15,929 trials

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency

NCT04561115

The purpose of this study is to demonstrate bioequivalence of IVIG-PEG with Gamunex-C (IVIG-C) at steady-state as determined by comparing total Immunoglobulin G (IgG) area under the concentration-time curve during the defined dosing interval (\[AUC0-τ\] either every 3 weeks \[AUC0-21 days\] or every 4 weeks \[AUC0-28 days\]) and maximum concentration in a dosing interval (Cmax) in participants diagnosed with primary humoral immunodeficiency (PI) currently receiving chronic IVIG replacement treatment.

Primary Immunodeficiency

Grifols Therapeutics LLC33 participantsStarted Sep 2020

Birmingham, Alabama, United States • North Palm Beach, Florida, United States • South Bend, Indiana, United States +7 more locations

TERMINATEDPhase 232 miles

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

NCT03519256

A study to evaluate the safety and tolerability of nivolumab or nivolumab Plus BMS-986205 with or without BCG in BCG-Unresponsive non-muscle invasive Bladder Cancer.

Urinary Bladder Neoplasms

Bristol-Myers Squibb142 participantsStarted Aug 2018

Los Angeles, California, United States • Riverside, California, United States • San Francisco, California, United States +85 more locations

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

Find Trials by Condition in Ohio

HLT® Meridian® TAVR Valve System Early Feasibility Study for Aortic Regurgitation

Single-Ascending Dose Study of JK07 in Subjects With HFpEF

Convalescent Plasma to Limit SARS-CoV-2 Associated Complications

A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease

BRITEPath- Phase 2

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies

Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC

Study of Diroximel Fumarate in the Real-World Setting

A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B

Rate of Atrial Fibrillation Through 12 Months in Patients With Recent Ischemic Stroke of Presumed Known Origin

Study Evaluating Flexitouch Plus With Connectivity on Compliance in 30 Patients With Breast Cancer-Related Lymphedema.

A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms

Thrombosomes® in Bleeding Thrombocytopenic Patients Study

Aligning Medications With What Matters Most

A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants